Panbela Therapeutics, Inc.(NASDAQ : PBLA)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.19%||162.94||0.7%||$1094.46m|
|MRK||Merck & Co., Inc.||0.78%||76.17||0.7%||$1032.73m|
|LLY||Eli Lilly & Co.||6.31%||230.80||1.1%||$953.07m|
|BMY||Bristol-Myers Squibb Co.||0.74%||65.75||1.0%||$629.63m|
|CNST||Constellation Pharmaceuticals, Inc.||0.18%||33.82||0.0%||$110.98m|
|RPRX||Royalty Pharma Plc||2.57%||43.28||0.2%||$106.65m|
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firmâ€™s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.